Dizal receives approval in China for NSCLC therapy

24 Aug 2023
www.pharmaceutical-technology.com
Drug ApprovalClinical ResultPhase 2CSCONDA
Dizal receives approval in China for NSCLC therapy
Preview
Source: Pharmaceutical Technology
NSCLC is the most widespread cancer in China. Credit: Egor_Kulinich / Shutterstock.com.
Dizal has received approval from China’s National Medical Products Administration (NMPA) for sunvozertinib to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations.
Sunvozertinib is intended for patients whose disease has advanced on or after platinum-based chemotherapy.
Recommended Reports
Dizal receives approval in China for NSCLC therapy
Preview
Source: Pharmaceutical Technology
ReportsChina Contract Manufacturing Market Outlook - Trends, Ambitions, Key Players, Investment and Valu... GlobalData
Dizal receives approval in China for NSCLC therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - TRV-734 in Opium Withdrawal Syndrome GlobalData
View allCompanies IntelligenceNational Medical Products AdministrationView all
Discovered by Dizal scientists, sunvozertinib is an irreversible EGFR inhibitorEGFR inhibitor designed to target a range of EGFR mutations with wild-type EGFR selectivity.
The approval from NMPA was based on the data from the pivotal study, WU-KONG6, which evaluated sunvozertinib in pretreated NSCLC patients with EGFR Exon20ins mutations.
The trial included 97 patients treated with the recommended Phase II dose of 300mg QD [four times per day].
WU-KONG6’s primary endpoint was a confirmed objective response rate (cORR). The resulting rate was 60.8%, a significant improvement on current treatment options.
Dizal CEO and chairman Xiaolin Zhang stated: “Sunvozertinib represents a groundbreaking achievement as the first Chinese innovative drug approved for EGFR Exon20ins NSCLC, showcasing Dizal’s remarkable efficiency and unwavering commitment to innovation.
“Our achievement of obtaining NDA approval in less than four years from enrolling the first patient sets an unprecedented benchmark for the rapid development of targeted lung cancer treatments.
“Furthermore, the commercial launch of sunvozertinib represents a significant milestone for Dizal, underscoring our capabilities from research and development to commercialisation.”
NSCLC is the most widespread cancer in China, with the highest rates of both incidence and mortality.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.